Janice Hodge
Nurse Practitioner · Rockville, MDNPI 1003803446
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,386 of the $7,392 with a category attached, or 86.4%. It is spread thinly across 35 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $25.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$1K
- Biohaven Pharmaceuticals, Inc.$907
- Novo Nordisk$760
- GSK$337
- Amgen$305
- plus $2K from 29 others
What the payments were for
- Consulting fees$97513%
- Travel & lodging$300%
- Food & beverage$6,38686%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 106 | $1,686 |
| AstraZeneca(2 entities) | 24 | $1,086 |
| Biohaven Pharmaceuticals, Inc. | 7 | $907 |
| Novo Nordisk | 36 | $760 |
| GSK | 11 | $337 |
| Amgen | 8 | $305 |
| Pfizer | 12 | $266 |
| Inspire Medical Systems, Inc. | 3 | $253 |
| Astellas Pharma US Inc | 9 | $199 |
| Exact Sciences | 4 | $176 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $138 |
| Merck | 7 | $135 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $121 |
| Amarin Pharma, Inc. | 6 | $116 |
| Lilly USA, LLC | 5 | $103 |
| Abbott | 5 | $83 |
| Axsome Therapeutics, Inc. | 3 | $80 |
| Daiichi Sankyo Inc. | 4 | $71 |
| Currax Pharmaceuticals LLC | 5 | $70 |
| Aerin Medical Inc. | 2 | $59 |
| Boehringer Ingelheim | 3 | $59 |
| Boston Scientific | 2 | $58 |
| Philips North America LLC | 2 | $54 |
| Medtronic | 1 | $35 |
| Johnson & Johnson | 2 | $34 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $30 |
| Bausch Health US, LLC | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Eisai Inc. | 1 | $22 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Genentech USA, Inc. | 2 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$800
- BREZTRI$364
- UBRELVY$247
- AIRSUPRA$211
- Prolia$175
- Inspire$143
- FARXIGA$124
- The Cologuard Plus Collection Kit$122
- Wegovy$122
- PREVNAR - 13$107
- TRUMENBA$107
- PREVNAR 20$107
- SHINGRIX$104
How this compares
$7,392 in reported general payments places this provider in the 95th percentile of 1,562 nurse practitioner providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 16 | $19,929 |
| FarxigaDapagliflozin Propanediol | 23 | $19,131 |
| Candesartan Cilexetil | 26 | $2,075 |
| Rosuvastatin Calcium | 61 | $1,776 |
| Atorvastatin Calcium | 143 | $1,585 |
| Levothyroxine Sodium | 89 | $777 |
| SynthroidLevothyroxine Sodium | 19 | $736 |
| Losartan Potassium | 52 | $673 |
| Amlodipine Besylate | 88 | $614 |
| Ezetimibe | 11 | $590 |
| Lisinopril | 69 | $484 |
| Metoprolol Succinate | 38 | $459 |
| Tamsulosin Hcl | 15 | $417 |
| Omeprazole | 21 | $403 |
| Escitalopram Oxalate | 21 | $398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $760 | $19,92916 claims |
| AstraZenecaFarxiga | $1,086 | $19,13123 claims |
| AbbVieSynthroid | $1,686 | $73619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,562 nurse practitioner providers in Maryland.
Other nurse practitioner in Rockville
- Morgan GaleRockville$292K
- Sherilyn BrinkleyBaltimore$100K
- Michelle TurnerBaltimore$94K
- Nelli ZafmanLutherville$67K
- Ellen LancasterFallston$52K
- Doris TateEaston$34K
- Zeev NemirovskyBaltimore$19K
- Martha ReilleyAnnapolis$18K
- Stephanie ZwonitzerAnnapolis$16K
- Jennifer MaglianoTimonium$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.